The Effect of G6PD Enzyme and Some Clinical Parameters in Hypertensive Heart Disease Patients

Background and Objective: "Due to its great incidence and the corresponding dangers of cardiovascular disease, hypertension is a major global public health concern. One of the most significant metabolite enzymes, glucose-6-phosphate dehydrogenase (G6PD) (also known as oxidoreductase; EC 1.1.1.1-49) is the primary enzyme and the key to the pentose phosphate pathway. It promotes the oxidation of glucose-6-phosphate (G-6-P) (NADP +) to preserve the pathways that many vital compounds use to produce life. People who have this oxidative damage status due to downregulated G6PD are more likely to develop cancer, diabetes, and cardiovascular diseases, among other degenerative ailments". Methodology: 200 "individuals between the ages of 30 and 69 who had hypertension and a control group were gathered. The following demographic information was noted: gender, age, height, weight, length of hypertension, length of treatment, and medical history, particularly fauvism. Measurements were also made of body mass index and blood pressure. One blood sample was taken from each patient and 5 elements including G6PD existence and activity, fasting plasma glucose, plasma Calcium, Magnesium and troponin".Results: G6PD "activity was substantially higher (P<0.05) in those in the control group. G6PD mean activity was substantially higher in the control group (P<0.05) and in participants with a BMI < 25 (P<0.05) when it came to hypertension. The control group's G6PD mean activity was substantially higher than that of the Ca,Mg hypertension control group (P<0.01). The relationship between troponin and hypertension was found to be positive (r=0.2681), with a higher concentration of troponin throughout the groups under study and a positive correlation with g6pd".Conclusion: "The biochemical marker G6PD activity can be used to diagnose hypertension, which can have major consequences and raise G6PD activity. This problem intensifies the damage caused by hypertension as a result of an improper antioxidation process. Obesity and dyslipidemia concurrently may exacerbate the effects of oxidative stress and hypertension.